Find policies, billing codes, payers, states, and providers
CPT 80161: Carbamazepine –10,11–epoxide Quantitative Assay
CPT code 80161 designates a quantitative laboratory assay for the –10,11–epoxide metabolite of carbamazepine in patient specimens such as serum. This metabolite testing supports clinical management by identifying elevated levels that may indicate toxicity from carbamazepine, an anticonvulsant used for epilepsy and some neurologic and psychiatric conditions. The code is relevant nationally to hospital and outpatient clinical laboratories, toxicology services, and clinicians who monitor therapeutic drug safety.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise clinical context for the assay, typical sites of service, common billing modifiers and payer coverage patterns where available. The publication summarizes billing and coding considerations, benchmarks for utilization, and policy or coverage updates that affect laboratory processing of antiepileptic drug metabolite testing. Clinical implications for monitoring carbamazepine toxicity and the role of quantitative metabolite measurement in medication safety are also presented.
Data not available in the input: associated taxonomies, ICD-10 diagnoses, related CPT codes, and specific payer policy language.
Customize your policy alerts
Sign up for cpt 80161 policy alerts
Get alerted when payer policies referencing 80161 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 80161 describes a laboratory quantitative assay for the carbamazepine –10,11–epoxide metabolite performed by a lab analyst on a patient specimen such as serum. The test measures the metabolite level of carbamazepine, an anticonvulsant medication used to treat epilepsy and certain neurologic and psychiatric disorders. Measured metabolite concentrations can be used to monitor possible medication toxicity and guide clinical interpretation of carbamazepine therapy.
Service type: Clinical laboratory service — quantitative drug metabolite assay
Typical site of service: Clinical laboratory or hospital laboratory (ambulatory or inpatient specimen collection and processing)